Purple Biotech

Company Overview

Snapshot

Founded in August 1968, Purple Biotech operates with 11–50 employees and has raised a total of $94.6 million across 11 funding rounds. The company recently announced new data from its CAPTN-3 platform tri-specific IM1240 in April 2026.

Business overview

Purple Biotech is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. The company's oncology pipeline includes NT219 and CM24, which target various mechanisms to enhance anti-tumor immune responses. These therapies are designed to treat solid tumors and other cancers, serving the broader healthcare and life sciences sector, specifically within pharmaceuticals and drugs discovery & development.

Strategic signal

In March 2026, Purple Biotech announced an AI collaboration with Converge Bio to accelerate the development of its next-generation tri-specific antibody platform. This partnership signals a strategic move towards leveraging advanced technology to enhance drug discovery and development, potentially speeding up the delivery of innovative cancer treatments and strengthening the company's competitive edge in the biotechnology sector.

Company Intelligence Q&A

What was the outcome of Purple Biotech's Q1 2026 financial results and business highlights?

In May 2026, Purple Biotech reported its first quarter 2026 financial results and business highlights, including new data from its CAPTN-3 platform tri-specific IM1240 and the establishment of a Scientific Advisory Board to support its development.

What was the significance of the CAPTN-3 platform data announced in April 2026?

In April 2026, Purple Biotech announced new data from its CAPTN-3 platform tri-specific IM1240, which is part of its efforts to develop therapies that overcome tumor immune evasion and drug resistance.

What strategic move did Purple Biotech make in March 2026 regarding its antibody platform?

In March 2026, Purple Biotech announced an AI collaboration with Converge Bio to accelerate the development of its next-generation tri-specific antibody platform, aiming to enhance its drug development capabilities.

What was the outcome of Purple Biotech's compliance with Nasdaq in March 2026?

In March 2026, Purple Biotech regained compliance with Nasdaq listing requirements, indicating a positive resolution to previous compliance issues.

What was the key finding from Purple Biotech's toxicology study for IM1240 in January 2026?

In January 2026, Purple Biotech achieved a toxicology milestone for its tri-specific antibody, IM1240, demonstrating an expanded therapeutic window and favorable safety profile, paving the way for future clinical trials.